31 Aug 2016 14:17
31 August 2016
Â
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Â
Change of Registered Office
Â
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it has changed the address of its registered office to Unit 20, Ash Way, Thorp Arch Estate, Wetherby, LS23 7FA.
Â
ENDS
Â
Notes to Editors
Â
For further information from Avacta Group plc, please contact:
Â
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer  | Tel: +44 (0) 844 414 0452 www.avacta.com |
Numis Securities Limited Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking  WG Partners David Wilson Nigel Barnes Claes Spang | Tel: +44 (0) 207 260 1000 www.numiscorp.com   Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk  |
 FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins |  Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
Â
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Â
Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.
Â
Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Â